**Table S1. Individual data for 4 eyes with no vision loss at the screening and inclusion visits**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **Patient #12** | **Patient #15** | **Patient #22** | **Patient #26** |
| **Age (years)** | | | 20 | 20 | 26 | 32 |
| **Gender** | | | F | M | F | M |
| **Duration of vision loss in *affected* eye (days) a** | | | 155 | 90 | 57 | 49 |
| **Unaffected eye** | | | Left | Right | Left | Right |
| **BCVA (LogMAR)**  **(Snellen)** | | *Screening* | -0.2 20/13 | -0.3 20/10 | 0.0 20/20 | -0.1 20/16 |
| *Inclusion* | -0.2 20/13 | -0.2 20/13 | -0.1 20/16 | -0.1 20/16 |
| **CS (LogCS)** | | *Screening* | 1.65 | 1.65 | 1.65 | 1.65 |
| *Inclusion* | 1.35 | 1.65 | 1.5 | 1.65 |
| **HVF (dB)** | **MD** | *Screening* | NR | NR | NR | -1.14 |
| *Inclusion* | NR | -2.4 | -1.9 | NR |
| **PSD** | *Screening* | NR | NR | NR | 1.87 |
| *Inclusion* | NR | 1.6 | 1.29 | NR |
| **SD-OCT** | **GCL Macular Volume (mm3)** | *Screening* | 1.06 | 1.28 | 1.06 | 1.27 |
| *Inclusion* | 1.07 | 1.27 | 1.01 | 1.24 |
| **ETDRS Total Macular Volume (mm3)** | *Screening* | 8.44 | 9.53 | 8.72 | 9.34 |
| *Inclusion* | 8.48 | 9.63 | 8.69 | 9.31 |
| **PMB RNFL Thickness (µm)** | *Screening* | 62 | 118 | 66 | 65 |
| *Inclusion* | 64 | 128 | 69 | 69 |
| **RNFL Quadrant Temporal (µm)** | *Screening* | 88 | 141 | 81 | 80 |
| *Inclusion* | 88 | 154 | 85 | 85 |
| **RNFL Average Thickness (µm)** | *Screening* | 107 | 143 | 95 | 118 |
| *Inclusion* | 108 | 149 | 97 | 121 |
| Abbreviations: BCVA = best-corrected visual acuity; CS = contrast sensitivity; ETDRS = Early-Treatment Diabetic Retinopathy Study; GCL = ganglion cell layer; HVF = Humphrey visual field; MD = mean deviation; NR = not reliable; PMB = papillomacular bundle; PSD = pattern standard deviation; RNFL = retinal nerve fiber layer; SD-OCT = spectral-domain optical coherence tomography.  a: Duration of vision loss in contralateral affected eye was reported at screening. | | | | | | |